“The key driver for the surge in market size is the rise in number of cases of Spinal Cord Injury, rising geriatric population, and launch of novel upcoming drugs during the forecast period (2022-2032)”
The Spinal Cord Injury market report provides current treatment practices, Spinal Cord Injury emerging drugs, Spinal Cord Injury market share of the individual therapies, current and forecasted Spinal Cord Injury market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Spinal Cord Injury treatment practice/algorithm, Spinal Cord Injury market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Spinal Cord Injury market.
Key takeaways from the Spinal Cord Injury Market Research Report
- According to DelveInsight, the Spinal Cord Injury market in 7MM is expected to witness a major change in the study period 2019-2032.
- In 2022, total Spinal Cord Injury diagnosed cases in the US was assessed to be ~326,000 which is expected to increase in the forecast period.
- Males are affected more as compared to females, in case of Spinal Cord Injury.
- The leading Spinal Cord Injury Companies include StemCyte, Lineage Cell Therapeutics (NYSE: LCTX), Kringle Pharma, AbbVie (NYSE: ABBV), Nipro Corporation, ReNetX Bio, Inc., Neurofix, Eli Lilly and Company (NYSE: LLY), ICOS Corporation (NYSE: ICOS), Eusol Biotech Co Ltd, Moleac Pte Ltd., Kringle Pharma Inc, Acorda Therapeutics (NYSE: ACOR), Bayer, GlaxoSmithKline (NYSE: GSK), Pfizer (NYSE: PFE), and others.
- Promising Spinal Cord Injury Pipeline Therapies include Denosumab (Prolia), pregabalin, Vardenafil (Levitra, BAY38-9456), Fampridine-SR, KP-100IT, NeuroAiD, ES135, tadalafil, and others.
Discover more about therapies set to grab major Spinal Cord Injury Market Share @ Spinal Cord Injury Market Size
Spinal Cord Injury Overview
Spinal cord injury (SCI) is a serious medical condition that causes the functional, psychological, and socioeconomic disorders. Long-term, secondary medical complications are common and play an important role in the continuum of care for patients with SCI. Complications are a frequent cause of morbidity and mortality and lead to increased rates of re-hospitalization, loss of employability, and decreased quality of life.
Spinal Cord Injury Epidemiology Segmentation in the 7MM
- Total Spinal Cord Injury Cases
- Spinal Cord Injury Gender-specific Cases
- Spinal Cord Injury Cause-specific Cases
- Spinal Cord Injury Diagnosed Cases
- Total Spinal Cord Injury Cases at Neurological Level
Recent Developmental Activities in the Spinal Cord Injury Treatment Landscape
- KP-100IT (Kringle Pharma) is an HGF that has been shown to exhibit a wide variety of physiological activities, not only as a mitogenic factor for liver cells but also as mitogenic, anti-apoptotic (cell death), morphogenic, and angiogenic factors for various other types of cells. Currently, the company is assessing KP-100IT in a Phase III clinical study in Subjects with acute spinal cord injury.
- NEURO-CELLS (Neuroplast) are derived from the bone marrow of the patient itself. The company’s technology calls on the self-healing capacity of non-manipulated stem cells, that the body itself is unable to leverage for neurodegenerative conditions due to the blood brain barrier. The EU has granted stem cell specialist Neuroplast orphan disease designation for traumatic spinal cord injury and fast-track development pathway for traumatic spinal cord injury (TSCI). Currently, the company is conducting Phase II/III clinical study of NEURO-CELLS to assess its efficacy and safety in (sub)acute spinal cord injury patients.
- ABT-555 (Abbvie) is a monoclonal antibody of the human immunoglobulin (Ig)G1 isotype that binds selectively to repulsive guidance molecule A (RGMa). ABT-555 (elezanumab) is being investigated to treat spinal cord injuries and acute ischemic stroke. RGMa is an inhibitor of axonal outgrowth and recognized as an important factor in inhibiting neuronal regeneration and functional recovery following central nervous system (CNS) damage. Elezanumab is being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke. AbbVie has received orphan drug and fast track designations from the US FDA for ABT-555 (elezanumab) to treat spinal cord injury (SCI). Currently, the drug is being studied in Phase II clinical study to assess the safety and efficacy in acute traumatic cervical spinal cord injury.
- MT-3921 (Mitsubishi Tanabe Pharma) is a novel humanized immunoglobulin G1 (IgG1) monoclonal antibody that binds to repulsive guidance molecule A(RGMa). In July 2021, the US FDA granted fast track designation to MT-3921 for the treatment of spinal cord injury. Currently, the company is assessing the efficacy and safety of MT-3921 in Phase II of clinical development in subjects with acute traumatic cervical spinal cord injury.
- AST-OPC1 (Lineage Cell Therapeutics) is an oligodendrocyte progenitor cell therapy that is currently in a Phase I/IIa multicenter clinical trial for acute spinal cord injuries (SCI). OPC1 has received a regenerative medicine advanced therapy (RMAT) and from the FDA, which include accelerated programs intended to facilitate the development and review process, including early interactions with US FDA during clinical development and enhanced favorability for marketing approval. Recently, in March 2023, the company announced its plans for a Type B meeting with FDA to discuss about amendment to the IND application for OPC 1 enabling clinical testing of a novel spinal cord delivery system in the second quarter of 2023.
Download the report to understand which factors are driving Spinal Cord Injury Epidemiology Trends @ Spinal Cord Injury Epidemiological Insights
Spinal Cord Injury Market Dynamics
The Spinal Cord Injury market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2023–2032.
Spinal Cord Injury Market Landscape
The landscape of Spinal cord injury (CSCI) management is quickly changing as the heterogeneity of patients, and long-term importance of key early interventions are increasingly being recognized. Combinatorial neuro-protective and neuroregenerative strategies are most likely to be effective moving forward given the multifaceted nature of the injury; however, this approach may require tailoring to specific patient subgroups. Overall, the rise in spinal cord injury patient population, increased funding by governmental bodies, and vigorous R&D activities are further expected to propel the SCI market during the forecast period (2023–2032).
To know more about Spinal Cord Injury Treatment options, visit @ Spinal Cord Injury Drugs
Spinal Cord Injury Emerging Drugs
- Symptomatic therapies (nifedipine, anticholinergic medications, α-blockers, analgesics, nonsteroidal anti-inflammatory drugs, opioids etc.)
- STEMIRAC (human [autologous] bone marrow derived mesenchymal stem cell): Nipro
- ABT-555 (elezanumab): Abbvie
- KP-100IT: Kringle Pharma
Spinal Cord Injury Key Companies
- StemCyte, Lineage Cell Therapeutics
- Kringle Pharma
- AbbVie
- Nipro Corporation
- ReNetX Bio Inc.
- Neurofix
- Eli Lilly and Company
- ICOS Corporation
- Eusol Biotech Co Ltd
- Moleac Pte Ltd
- Kringle Pharma Inc
- Acorda Therapeutics
- Bayer
- GlaxoSmithKline
- Pfizer
Spinal Cord Injury Pipeline Therapies
- Denosumab (Prolia)
- pregabalin
- Vardenafil (Levitra, BAY38-9456)
- Fampridine-SR
- KP-100IT
- NeuroAiD
- ES135
- Tadalafil
Learn more about the Spinal Cord Injury Pipeline Therapies in clinical trials @ Spinal Cord Injury Treatment Market
Scope of the Spinal Cord Injury Market Research Report
- Coverage- 7MM
- Spinal Cord Injury Companies- StemCyte, Lineage Cell Therapeutics (NYSE: LCTX), Kringle Pharma, AbbVie (NYSE: ABBV), Nipro Corporation, ReNetX Bio, Inc., Neurofix, Eli Lilly and Company (NYSE: LLY), ICOS Corporation (NYSE: ICOS), Eusol Biotech Co Ltd, Moleac Pte Ltd., Kringle Pharma Inc, Acorda Therapeutics (NYSE: ACOR), Bayer, GlaxoSmithKline (NYSE: GSK), Pfizer (NYSE: PFE) and others.
- Spinal Cord Injury Pipeline Therapies- Denosumab (Prolia), pregabalin, Vardenafil (Levitra, BAY38-9456), Fampridine-SR, KP-100IT, NeuroAiD, ES135, tadalafil, and others.
- Spinal Cord Injury Market Dynamics: Spinal Cord Injury Market Drivers and Barriers
- Spinal Cord Injury Market Access and Reimbursement, Unmet Needs, Future Perspectives
Discover more about Spinal Cord Injury Drugs in development @ Spinal Cord Injury Ongoing Clinical Trials Analysis
Table of Content
- Key Insights
- Executive Summary of Spinal Cord Injury (SCI)
- Competitive Intelligence Analysis for Spinal Cord Injury (SCI)
- Spinal Cord Injury (SCI): Market Overview at a Glance
- Spinal Cord Injury (SCI): Disease Background and Overview
- Patient Journey
- Spinal Cord Injury (SCI) Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Spinal Cord Injury (SCI) Unmet Needs
- Key Endpoints of Spinal Cord Injury (SCI) Treatment
- Spinal Cord Injury (SCI) Marketed Products
- Spinal Cord Injury (SCI) Emerging Therapies
- Spinal Cord Injury (SCI): Seven Major Market Analysis
- Attribute analysis
- 7MM: Spinal Cord Injury Market Outlook
- Access and Reimbursement Overview of Spinal Cord Injury (SCI)
- KOL Views
- Spinal Cord Injury Market Drivers
- Spinal Cord Injury Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Get in touch with our Business executive @ Spinal Cord Injury Market Drivers and Barriers
List of Top Selling Reports in 2023
B-Cell Maturation Antigen Targeted Therapies Market | Bag3-related Gene Therapies Market | Dyspepsia Market | Epidemic Parotitis Market | Familial Lipoprotein Lipase Deficiency Market | HDAC Inhibitors Market | Heart Pump Device Market | Inflammatory Pain Market | Japan Healthcare Outlook
Trending Reports:
- Thymic Carcinoma Market
- Neurostimulation Devices Market
- Osteoarthritis Market
- Sjogren’s Syndrome Market
- Hemodynamic Monitoring Systems Market
- Pediatric Obesity Market
- Global Electrophysiology Devices Market
- Acute Radiation Syndrome Market
- Bone Anchored Hearing Systems Market
- Bronchial Spasm Market
- Complicated Intra-Abdominal Infections Market
- Dermal Erythema Market
- Hip Replacement Devices Market
- Hpv-Induced Cancers Market
- Interbody Cages Market
- Meningioma Market
Latest Blogs by Delveinsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com